Evernorth Will Offer a Private-Label Stelara Biosimilar in 2025

Beginning in early 2025, Evernorth Health Services will offer clients and their members a private-label biosimilar of Stelara (ustekinumab). The interchangeable biosimilar will be produced for Evernorth’s affiliate private-label distributor, Quallent Pharmaceuticals, and will have a price that is more than 80% lower than the list price of Stelara. In a press release, Evernorth indicated that this represents an opportunity for significant savings.